In the current study, we set out to identify and test individualized treatment regimens for EGFR-driven GBM, using patient-derived cells (PDC) and patient-derived xenografts (PDX), guided by the samples’ genomic profiles and focusing on small molecule-based therapeutics. This evidence concerns the gene EGFR and glioblastoma.